306 related articles for article (PubMed ID: 28635633)
1. New Insights in Thyroid Cancer and p53 Family Proteins.
Manzella L; Stella S; Pennisi MS; Tirrò E; Massimino M; Romano C; Puma A; Tavarelli M; Vigneri P
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635633
[TBL] [Abstract][Full Text] [Related]
2. An update on molecular biology of thyroid cancers.
Omur O; Baran Y
Crit Rev Oncol Hematol; 2014 Jun; 90(3):233-52. PubMed ID: 24405857
[TBL] [Abstract][Full Text] [Related]
3. Update on thyroid cancer treatment.
Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
[TBL] [Abstract][Full Text] [Related]
4. Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma.
Bravo SB; García-Rendueles ME; Seoane R; Dosil V; Cameselle-Teijeiro J; López-Lázaro L; Zalvide J; Barreiro F; Pombo CM; Alvarez CV
Clin Cancer Res; 2005 Nov; 11(21):7664-73. PubMed ID: 16278386
[TBL] [Abstract][Full Text] [Related]
5. The p53-homologue p63 may promote thyroid cancer progression.
Malaguarnera R; Mandarino A; Mazzon E; Vella V; Gangemi P; Vancheri C; Vigneri P; Aloisi A; Vigneri R; Frasca F
Endocr Relat Cancer; 2005 Dec; 12(4):953-71. PubMed ID: 16322335
[TBL] [Abstract][Full Text] [Related]
6. P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression.
Preto A; Reis-Filho JS; Ricardo S; Soares P
Pathol Res Pract; 2002; 198(7):449-54. PubMed ID: 12234063
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy: a new hope for thyroid carcinomas.
Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
[TBL] [Abstract][Full Text] [Related]
8. Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment.
Manzella L; Massimino M; Stella S; Tirrò E; Pennisi MS; Martorana F; Motta G; Vitale SR; Puma A; Romano C; Di Gregorio S; Russo M; Malandrino P; Vigneri P
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269742
[TBL] [Abstract][Full Text] [Related]
9. Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors.
Antico Arciuch VG; Russo MA; Dima M; Kang KS; Dasrath F; Liao XH; Refetoff S; Montagna C; Di Cristofano A
Oncotarget; 2011 Dec; 2(12):1109-26. PubMed ID: 22190384
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin JA; Matsuo K; Karmakar A; Chen DL; Tang SH; Koeffler HP
J Clin Invest; 1993 Jan; 91(1):179-84. PubMed ID: 8423216
[TBL] [Abstract][Full Text] [Related]
11. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy.
Riesco-Eizaguirre G; Santisteban P
Endocr Relat Cancer; 2007 Dec; 14(4):957-77. PubMed ID: 18045949
[TBL] [Abstract][Full Text] [Related]
12. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.
Donghi R; Longoni A; Pilotti S; Michieli P; Della Porta G; Pierotti MA
J Clin Invest; 1993 Apr; 91(4):1753-60. PubMed ID: 8473515
[TBL] [Abstract][Full Text] [Related]
13. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
[TBL] [Abstract][Full Text] [Related]
14. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas.
La Perle KM; Jhiang SM; Capen CC
Am J Pathol; 2000 Aug; 157(2):671-7. PubMed ID: 10934169
[TBL] [Abstract][Full Text] [Related]
15. New approaches to thyroid cancer.
Cohen EE
Clin Adv Hematol Oncol; 2012 Apr; 10(4):255-6. PubMed ID: 22706487
[No Abstract] [Full Text] [Related]
16. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines.
Jossart GH; Epstein HD; Shaver JK; Weier HU; Greulich KM; Tezelman S; Grossman RF; Siperstein AE; Duh QY; Clark OH
J Clin Endocrinol Metab; 1996 Oct; 81(10):3498-504. PubMed ID: 8855792
[TBL] [Abstract][Full Text] [Related]
17. Multi-targeted approach in the treatment of thyroid cancer.
Zarebczan B; Chen H
Minerva Chir; 2010 Feb; 65(1):59-69. PubMed ID: 20212418
[TBL] [Abstract][Full Text] [Related]
18. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
19. Alterations of p53 and expression of WAF1/p21 in human thyroid tumors.
Zedenius J; Larsson C; Wallin G; Bäckdahl M; Aspenblad U; Höög A; Børresen AL; Auer G
Thyroid; 1996 Feb; 6(1):1-9. PubMed ID: 8777377
[TBL] [Abstract][Full Text] [Related]
20. SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways.
Grassi ES; Vezzoli V; Negri I; Lábadi Á; Fugazzola L; Vitale G; Persani L
Oncotarget; 2015 Nov; 6(34):36383-99. PubMed ID: 26415230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]